Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409536 | 0.90 | MAPT (0.80) | DNM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL410694 | 0.87 | MAPT (0.80) | DNM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL411195 | 0.83 | DNM1 (0.69) | DNM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL409461 | 0.83 | DNM1 (0.78) | DNM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL408965 | 0.82 | DNM1 (1.00) | DNM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL15132554 | 0.79 | DNM1 (0.71) | DNM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL411693 | 0.77 | ALDH1A1 (1.00) | DNM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL12960306 | 0.77 | DNM1 (0.68) | DNM1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL12259108 | 0.75 | MAPT (0.71) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL19559313 | 0.75 | DNM1 (0.78) | DNM1MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011127333-A2 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011127333-A2 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | DNM1 1556/4885MAPT 443/4885MEN1 56/4885 |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | DNM1 1556/4885MAPT 443/4885MEN1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.